NZ717921A - Microrna compounds and methods for modulating mir-21 activity - Google Patents

Microrna compounds and methods for modulating mir-21 activity Download PDF

Info

Publication number
NZ717921A
NZ717921A NZ717921A NZ71792112A NZ717921A NZ 717921 A NZ717921 A NZ 717921A NZ 717921 A NZ717921 A NZ 717921A NZ 71792112 A NZ71792112 A NZ 71792112A NZ 717921 A NZ717921 A NZ 717921A
Authority
NZ
New Zealand
Prior art keywords
nucleoside
activity
methods
modified
modulating mir
Prior art date
Application number
NZ717921A
Other languages
English (en)
Inventor
Balkrishen Bhat
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Priority claimed from NZ616748A external-priority patent/NZ616748B2/en
Publication of NZ717921A publication Critical patent/NZ717921A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
NZ717921A 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity NZ717921A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01
NZ616748A NZ616748B2 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Publications (1)

Publication Number Publication Date
NZ717921A true NZ717921A (en) 2017-09-29

Family

ID=46025979

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ717921A NZ717921A (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Country Status (30)

Country Link
US (7) US9181547B2 (https=)
EP (3) EP3211082B1 (https=)
JP (2) JP6320292B2 (https=)
KR (2) KR102055172B1 (https=)
CN (3) CN103620035B (https=)
AU (4) AU2012249851B2 (https=)
BR (1) BR112013027187A2 (https=)
CA (2) CA3165397A1 (https=)
CL (1) CL2013003105A1 (https=)
CO (1) CO6821889A2 (https=)
CY (1) CY1120304T1 (https=)
DK (2) DK3211082T3 (https=)
EA (1) EA025894B1 (https=)
ES (2) ES2621863T3 (https=)
HR (2) HRP20170557T2 (https=)
HU (2) HUE031595T2 (https=)
IL (3) IL229032B (https=)
LT (2) LT3211082T (https=)
MX (5) MX2013012452A (https=)
MY (2) MY175336A (https=)
NZ (1) NZ717921A (https=)
PH (1) PH12013502199A1 (https=)
PL (2) PL2702155T3 (https=)
PT (2) PT3211082T (https=)
RS (1) RS61775B1 (https=)
SG (1) SG194636A1 (https=)
SI (2) SI3211082T1 (https=)
TW (2) TWI698445B (https=)
UA (1) UA115652C2 (https=)
WO (1) WO2012148952A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP3211082B1 (en) 2011-04-25 2021-02-17 Sanofi Microrna compounds and methods for modulating mir-21 activity
EP2836219A1 (en) * 2012-04-10 2015-02-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for the treatment of nonalcoholic steatohepatitis
PE20142404A1 (es) 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
WO2015113922A1 (en) * 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Poly oligomer compound with biocleavable conjugates
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
US20190127736A1 (en) * 2016-04-29 2019-05-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
CN111386351A (zh) 2017-09-22 2020-07-07 华盛顿大学 细胞分子的原位组合标记
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
EP3790972A1 (en) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤
CN120505413A (zh) * 2025-07-15 2025-08-19 湖南工程学院 一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508317A (en) 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2390331B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
US20080187508A1 (en) 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
WO2007027894A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
CA2648132C (en) 2006-04-03 2019-05-28 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2666859B1 (en) * 2006-04-03 2019-01-02 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP3192788A1 (en) 2006-10-03 2017-07-19 Arbutus Biopharma Corporation Lipid containing formulations
EP2489742A1 (de) 2006-10-09 2012-08-22 Julius-Maximilians-Universität Würzburg MicroRNA (MIRNA) zur Diagnose und Therapie von Herzerkrankungen
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en) 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
EP2217248B1 (en) 2007-10-29 2016-11-30 Regulus Therapeutics Inc. Targeting micrornas for the treatment of liver cancer
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010099161A1 (en) * 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
CA2765129A1 (en) * 2009-06-08 2010-12-16 Miragen Therapeutics Chemical modification motifs for mirna inhibitors and mimetics
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
EP3211082B1 (en) 2011-04-25 2021-02-17 Sanofi Microrna compounds and methods for modulating mir-21 activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
PE20142404A1 (es) 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN104955950B (zh) 2012-09-26 2019-04-26 米尔克斯治疗学公司 具有改善的脱靶特征谱的寡核苷酸
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
HRP20210616T1 (hr) 2021-05-28
LT2702155T (lt) 2017-05-10
US9790496B2 (en) 2017-10-17
IL266529A (en) 2019-07-31
NZ616748A (en) 2016-03-31
HRP20170557T1 (hr) 2017-06-16
ES2621863T9 (es) 2020-02-13
WO2012148952A1 (en) 2012-11-01
JP2014518619A (ja) 2014-08-07
JP6320292B2 (ja) 2018-05-09
CA2833615A1 (en) 2012-11-01
EP2702155B1 (en) 2017-02-01
CN113151272A (zh) 2021-07-23
MX2022006595A (es) 2022-07-01
EP3211082A1 (en) 2017-08-30
AU2012249851B2 (en) 2017-06-08
AU2012249851A8 (en) 2013-11-14
TWI607016B (zh) 2017-12-01
PT2702155T (pt) 2017-04-03
CA2833615C (en) 2022-08-30
US20200291400A1 (en) 2020-09-17
JP2018121646A (ja) 2018-08-09
MX2019003090A (es) 2019-07-18
PH12013502199A1 (en) 2014-01-27
CN113249381A (zh) 2021-08-13
RS61775B1 (sr) 2021-05-31
ES2621863T3 (es) 2017-07-05
EP3211082B1 (en) 2021-02-17
SI3211082T1 (sl) 2021-08-31
US12331294B2 (en) 2025-06-17
LT3211082T (lt) 2021-05-10
HK1243130A1 (en) 2018-07-06
CN103620035A (zh) 2014-03-05
CO6821889A2 (es) 2013-12-31
US20220098583A1 (en) 2022-03-31
DK2702155T3 (en) 2017-05-01
EP2702155B9 (en) 2020-01-01
EP3933040A1 (en) 2022-01-05
PL2702155T3 (pl) 2017-09-29
MX393138B (es) 2025-03-24
BR112013027187A2 (pt) 2017-06-06
HUE054129T2 (hu) 2021-08-30
MX2019003089A (es) 2019-07-18
US20120270928A1 (en) 2012-10-25
DK3211082T3 (da) 2021-05-10
KR20190063482A (ko) 2019-06-07
TWI698445B (zh) 2020-07-11
IL229032A0 (en) 2013-12-31
ES2868950T3 (es) 2021-10-22
HRP20170557T2 (hr) 2020-02-21
KR102055172B1 (ko) 2020-01-23
US8912161B2 (en) 2014-12-16
PT3211082T (pt) 2021-04-28
TW201300404A (zh) 2013-01-01
EP2702155A1 (en) 2014-03-05
MY175336A (en) 2020-06-19
CY1120304T1 (el) 2019-07-10
US20160138016A1 (en) 2016-05-19
US9181547B2 (en) 2015-11-10
US20140107183A1 (en) 2014-04-17
CN103620035B (zh) 2021-04-23
US20180155719A1 (en) 2018-06-07
KR20140033062A (ko) 2014-03-17
CL2013003105A1 (es) 2014-08-01
MX2013012452A (es) 2014-11-21
TW201811812A (zh) 2018-04-01
UA115652C2 (uk) 2017-12-11
AU2012249851A1 (en) 2013-10-31
MX2022000212A (es) 2022-04-01
AU2020201403A1 (en) 2020-03-12
EA025894B1 (ru) 2017-02-28
EA201391492A1 (ru) 2014-04-30
SG194636A1 (en) 2013-12-30
SI2702155T1 (sl) 2017-07-31
AU2017219156B2 (en) 2020-01-02
CA3165397A1 (en) 2012-11-01
US20140329887A1 (en) 2014-11-06
AU2017219156A1 (en) 2017-09-21
HUE031595T2 (en) 2017-07-28
MY187685A (en) 2021-10-11
IL273381A (en) 2020-05-31
AU2022203067A1 (en) 2022-05-26
IL229032B (en) 2021-01-31
PL3211082T3 (pl) 2021-08-02

Similar Documents

Publication Publication Date Title
NZ717921A (en) Microrna compounds and methods for modulating mir-21 activity
NZ630591A (en) Microrna compounds and methods for modulating mir-21 activity
NZ630890A (en) Microrna compounds and methods for modulating mir-122
NZ630596A (en) Methods for treatment of alport syndrome
NZ616512A (en) Modulation of hepatitis b virus (hbv) expression
MX2024001181A (es) Oligomeros antisentido y metodos de uso de los mismos para el tratamiento de enfermedades asociadas con el gen alfa-glucosidasa acida.
NZ630800A (en) Methods of preparing substituted nucleotide analogs
MX2021005357A (es) Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos.
NZ603339A (en) Modulation of transthyretin expression
NZ631512A (en) Compositions and methods for modulating apolipoprotein (a) expression
NZ629428A (en) Substituted nucleosides, nucleotides and analogs thereof
NZ602618A (en) Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
RU2015133252A (ru) Лечение возрастной макулярной дегенерации
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
WO2018102452A3 (en) Using substituted pyrazole compounds for treatment of hyperproliferative diseases
HK1203075A1 (en) Substituted phosphorothioate nucleotide analogs
PH12015502273A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015501953A1 (en) Substituted nucleotide analogs
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
NZ599032A (en) Modulation of huntingtin expression
NZ631132A (en) Exon skipping compositions for treating muscular dystrophy
EA201171335A1 (ru) Вектор гена
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
JP2013531491A5 (https=)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 APR 2019 BY SPRUSON + FERGUSON

Effective date: 20180131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 APR 2020 BY CPA GLOBAL

Effective date: 20190314

ASS Change of ownership

Owner name: SANOFI, FR

Effective date: 20190731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 APR 2021 BY CPA GLOBAL

Effective date: 20200312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 APR 2022 BY CPA GLOBAL

Effective date: 20210312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 APR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250313